# Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines

> **NCT01224015** · PHASE3 · COMPLETED · sponsor: **Allergan** · enrollment: 684 (actual)

## Conditions studied

- Facial Rhytides
- Crow's Feet Lines
- Glabellar Lines

## Interventions

- **DRUG:** normal saline
- **BIOLOGICAL:** onabotulinumtoxinA 44 U
- **BIOLOGICAL:** onabotulinumtoxinA 24 U

## Key facts

- **NCT ID:** NCT01224015
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2011-10
- **Final completion:** 2012-02
- **Target enrollment:** 684 (ACTUAL)
- **Last updated:** 2014-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01224015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01224015, "Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01224015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*